Henry Ford Health

Henry Ford Health Scholarly Commons
Sleep Medicine Articles

Sleep Medicine

9-1-2020

Objective sleep disturbance is associated with poor response to
cognitive and behavioral treatments for insomnia in
postmenopausal women
David A. Kalmbach
Henry Ford Health, DKalmba1@hfhs.org

Philip Cheng
Henry Ford Health, PCHENG1@hfhs.org

Thomas Roth
Henry Ford Health, TRoth1@hfhs.org

Chaewon Sagong
Henry Ford Health, csagong1@hfhs.org

Christopher L. Drake
Henry Ford Health, cdrake1@hfhs.org

Follow this and additional works at: https://scholarlycommons.henryford.com/sleepmedicine_articles

Recommended Citation
Kalmbach DA, Cheng P, Roth T, Sagong C, and Drake CL. Objective sleep disturbance is associated with
poor response to cognitive and behavioral treatments for insomnia in postmenopausal women. Sleep
Med 2020; 73:82-92.

This Article is brought to you for free and open access by the Sleep Medicine at Henry Ford Health Scholarly
Commons. It has been accepted for inclusion in Sleep Medicine Articles by an authorized administrator of Henry
Ford Health Scholarly Commons.

Sleep Medicine 73 (2020) 82e92

Contents lists available at ScienceDirect

Sleep Medicine
journal homepage: www.elsevier.com/locate/sleep

Original Article

Objective sleep disturbance is associated with poor response to
cognitive and behavioral treatments for insomnia in postmenopausal
women
David A. Kalmbach , Philip Cheng , Thomas Roth , Chaewon Sagong ,
Christopher L. Drake *
Thomas Roth Sleep Disorders & Research Center, Henry Ford Health System, Detroit, MI, 48202, USA

a r t i c l e i n f o

a b s t r a c t

Article history:
Received 4 December 2019
Received in revised form
19 April 2020
Accepted 28 April 2020
Available online 7 May 2020

Study objectives: To determine whether insomnia patients with objective sleep disturbance are less
responsive to cognitive and behavioral treatments than those without objective sleep disturbance,
characterize effects of insomnia therapy on objective sleep, and determine whether reductions in
nocturnal cognitive arousal correspond to changes in objective sleep.
Methods: Secondary analysis of a single-site, randomized controlled trial. 113 postmenopausal women
(56.40 ± 5.34 years) with menopause-related insomnia disorder were randomized to three treatment
conditions: cognitive-behavioral therapy for insomnia (CBTI), sleep restriction therapy (SRT), or sleep
education control. Primary outcomes were the Insomnia Severity Index (ISI) and polysomnography (PSG)
sleep parameters and were collected at pretreatment, posttreatment, and six-month follow-up.
Results: Patients with lower pretreatment PSG sleep efﬁciency had lower rates of insomnia remission
after active treatment relative to those with higher sleep efﬁciency (37.8% vs 61.8%). Neither CBTI and SRT
produced clinically meaningful effects on PSG sleep. Exploratory analyses revealed that reductions in
nocturnal cognitive arousal were associated with decreases in PSG sleep latency, but not wake after sleep
onset.
Conclusions: Our ﬁndings support an emerging literature suggesting that insomnia patients with
objective sleep disturbance may have blunted response to insomnia therapy. Research is needed to
enhance treatments to better improve insomnia in patients with objective sleep disturbance. A lack of
observed CBTI and SRT effects on PSG sleep suggests that these therapies may be presently ill-designed to
improve objective sleep. Nocturnal cognitive arousal may represent an entry point to improve objective
sleep latency in insomnia.
Name: Behavioral Treatment of Menopausal Insomnia: Sleep and Daytime Outcomes. URL: clinicaltrials.gov. Registration: NCT01933295.
© 2020 Elsevier B.V. All rights reserved.
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1. Introduction
Polysomnography (PSG) is the gold standard tool for the
objective quantiﬁcation of sleep and assessing most sleep disorders
[1]. Yet, PSG has a complex history with insomnia in regard to its
usefulness for evaluating, treating, and understanding the etiology
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of the disorder. This is reﬂected in diagnostic systems for sleep
disorders (current and prior iterations of Diagnostic and Statistical
Manual of Mental Disorders [2] [DSM] and International Classiﬁcation of Sleep Disorders [3] [ICSD]) that deﬁne insomnia disorder
as a symptom-based condition without PSG criteria. Weak empirical support for the diagnostic utility of PSG for insomnia led to
recommendations against its use in routine evaluations, except to
assess for other sleep disorders that can co-occur with or contribute
to sleep complaints (eg, sleep apnea) [4e6]. Evidence casting doubt
on the utility of PSG in insomnia includes discrepancy between
patient-reported sleep and objective sleep ﬁndings, little or no
reliable difference in objective sleep between insomnia patients
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and healthy sleepers, and data suggesting that changes in objective
sleep are unnecessary for successful alleviation of insomnia with
therapy [7e9]. Clinicians and researchers have thus considered
patient-reported symptoms as a better indicator of the clinical
experience of insomnia. Consequently, objective sleep assessment
in insomnia has largely fallen by the wayside.
Although the insomnia patient population as a whole does not
reliably exhibit objective sleep disturbances, a subset of the population does. Accumulating evidence suggests that insomnia disorder may be comprised of two broad phenotypes: insomnia with
and without objective sleep disturbance [8,10,11]. Even so, there is
no universal consensus on how objective sleep disturbance should
be operationalized in insomnia (eg, total sleep time < 6 h, sleep
latency or wake after sleep onset > 30 min, etc.). Nevertheless, the
distinction is important as insomnia patients with objective sleep
disturbances have poorer stress regulation, more comorbidities,
and poorer long-term prognoses relative to those with normal
objective sleep [10,11]. As insomnia with objective sleep disturbance may have a different etiology and stronger biological basis
than insomnia without objective sleep ﬁndings [10], researchers
have taken interest in potential differences in treatment responsivity by phenotype.
These clinical trials focused on insomnia with vs without
objective short sleep (<6 h total sleep time on PSG or actigraphy)
and have produced mixed results. In two trials, insomnia patients
with objective short sleep, relative to those with normal sleep
duration, had blunted response to cognitive behavioral therapy for
insomnia (CBTI) [12,13], which is gold standard treatment for
insomnia [14]. In contrast, three other trials showed no difference
in treatment response between the normal sleep duration and
short sleep insomnia phenotypes [15e17]. As no clear patterns in
methodology distinguish studies that support vs refute differential
treatment response, it is unclear why such a degree of inconclusion
with markedly opposing ﬁndings was produced. Although all
studies used the total sleep time < 6 h operationalization for
objective sleep disturbance, it is possible that a lack of established
criteria for an objective sleep disturbance phenotype contributed in
part to these mixed results; particularly as objective sleep disturbance may manifest in ways other than total sleep time < 6 h.
Further complicating the matter of objective sleep disturbance
and insomnia therapy, overwhelming evidence suggests that
cognitive and behavioral interventions have minimal or no effect
on objective sleep disturbance [9]. As clinical trials of cognitive and
behavioral treatments for insomnia have traditionally focused on
patient-reported sleep symptoms, the lack of improvement in
objective sleep and the potential importance of such effects has
been downplayed. A recent review identiﬁed only ﬁve high quality
CBTI trials that reported PSG outcomes, none of which required
objective sleep criteria for trial entry [9]. In-line with recent interest in objective sleep disturbance as an indicator of insomnia
morbidity, mortality, and treatment-resistance [8,10e13], there has
been renewed emphasis to better understand the effects of
insomnia therapies on objective sleep and identifying how objective sleep outcomes can be improved [18].
The present report was a secondary analysis of a single-site RCT
comparing CBTI, sleep restriction therapy (SRT; a single component
of CBTI and effective standalone treatment), and sleep hygiene
education control (SHE) for the treatment of menopause-related
DSM-52/ICSD-33 insomnia disorder in a sample of 150 postmenopausal women. See reports by Drake et al., and Kalmbach
et al., for outcome data pertaining to insomnia, sleep diaries,
depression, and daytime function [19e21]. In this secondary analysis, we (1) tested pretreatment objective sleep disturbance as a
potential moderator of treatment response, and (2) tested effects of
cogitative-behavioral therapy for insomnia (CBTI) and SRT on
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objective sleep disturbance relative to control. Based on proposals
that insomnia with objective ﬁndings represents a more severe and
biologically-based phenotype of the disorder, we hypothesized that
patients with lower PSG sleep efﬁciency before treatment would
report greater insomnia symptoms after CBTI and SRT relative to
those with higher pretreatment sleep efﬁciency. We predicted no
such pattern would be observed in the control condition. Importantly, we chose to test sleep efﬁciency as a moderator as it captures
all manifestations of objective nocturnal wakefulness (sleep latency, wake after sleep onset, short sleep duration) and because no
universally accepted cutoff deﬁning objective sleep disturbance in
insomnia exists.
Second, a lack of objective sleep criteria for clinical trial entry
has been identiﬁed as a limitation of prior RCTs evaluating CBTI
effects on objective sleep due to restricted range and potential
insufﬁcient statistical power to detect effects. The present RCT
required objective sleep disturbance for entry. When this study was
initially proposed, our team hypothesized that CBTI and SRT would
improve objective sleep. However, meta-analytic data published in
the interim [9] changed our expectations, thus we predicted that
neither CBTI nor SRT would improve objective sleep relative to
control, despite our PSG inclusion criteria.
In an exploratory analysis based on data from our lab and others
showing that cognitive arousal and rumination is associated with
objective sleep disturbance [22e27], we conducted posthoc analyses to investigate whether changes in nocturnal cognitive arousal
were associated with changes in PSG sleep latency and wake after
sleep onset, irrespective of treatment condition (as we hypothesized no treatment effects). This exploratory analysis was conducted in attempt to identify therapeutic targets associated with
changes in objective sleep.
2. Methods
2.1. Subjects and setting
This trial was conducted in a six-hospital health system in metro
Detroit, Michigan, USA. Patients were recruited from the health
system in primary care and sleep medicine clinics, from the community via newspaper advertisements, and from a database of prior
sleep center studies. Inclusionary criteria included having 12
consecutive months without menses and self-reported wake after
sleep onset  1 h per night at least three nights per week, as well as
meeting criteria for DSM-5 insomnia disorder that onset or exacerbated during the peri- or postmenopausal period per clinical
interview with a registered nurse with specialty training in
behavioral sleep medicine. Inclusionary criteria regarding objective
sleep disturbance required women exhibit mean wake after sleep
onset of 45 min or more on two overnight PSG studies (adaptation
night þ baseline night, neither of which could have wake after sleep
onset < 30 min). Exclusionary criteria included prior or current
DSM-5 major depression per diagnostic interview, sleep-wake
disorders other than insomnia (examined on PSG adaptation
night and per patient report), and medications inﬂuencing sleep.
Women receiving hormone replacement therapy were eligible to
participate.
Participants were randomized to one of three conditions: SHE,
SRT, and CBTI. Randomization was conducted using 150 allocations
(50 per group) that were ordered randomly and concealed in envelopes. Group allocation for each participant was then assigned
using the order of concealed envelopes. While double-blind could
not be achieved given the nature of the behavioral interventions,
subjects were not informed which treatments were considered
control versus active, or of the speciﬁc hypotheses. Assessments of
self-reported insomnia symptoms (via online surveys) and
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objective sleep parameters (via in-lab overnight PSG were collected
prior to treatment, at posttreatment (within two weeks of
completing treatment), and six months after treatment completion.
2.2. Polysomnography assessments and schedule
The study protocol included four overnight laboratory PSG
studies. Night 1: Subjects who passed the in-person screening
interview then underwent a PSG adaptation/screening night with a
montage routinely used to rule out sleep disorders other than
insomnia disorder such as obstructive sleep apnea and periodic
limb movement disorder (apnea-hypopnea index > 10, periodic
limb movement index with arousal > 10). Night 2: A week later,
patients underwent a second PSG night, which was used to help
determine eligibility (see Subjects and setting section above) and
served as the pretreatment baseline night to which posttreatment
and follow-up data would be compared. Night 3: Within two weeks
of completing treatment, subjects underwent a third PSG study to
record posttreatment objective sleep disturbance. Night 4: Six
months later, subjects underwent the ﬁnal PSG study to record
longer-term objective sleep. For all subjects, overnight PSG study
bedtimes were scheduled in accordance with self-reported habitual
bedtimes and ended 8 h after lights out.
2.3. Treatment conditions
Sleep hygiene education (SHE), ie, minimal intervention control
condition. Women randomized to the online sleep hygiene education condition received six weekly emails including general, nonpersonalized information on the following topics: the basics of
endogenous sleep regulation; the impact of sleep on health problems such as obesity, diabetes, and hypertension; the effects of
stimulants and other sleep-disruptive substances; the relationship
between sleep, diet, and exercise; and tips on creating a sleepconducive bedroom environment. Sleep hygiene is neither the
primary cause nor a sufﬁcient therapeutic target in insomnia disorder and therefore served as an ideal minimal intervention control
condition and real-world comparator [28].
Cognitive-behavioral therapy for insomnia (CBTI) was one of two
active treatments in this RCT. Women randomized to CBTI
completed six face-to-face sleep therapy sessions with a registered
nurse who specializes in behavioral sleep medicine. CBTI is a
structured, multi-modal treatment that targets sleep-disruptive
behaviors and beliefs (see Ref. [29]). Data from clinical trials
consistently show that CBTI is as efﬁcacious as pharmacological
treatment in the short-term, but produces superior treatment
response in the long-term [14,30]. CBTI patients received six
weekly sessions, which covered behavioral (sleep restriction and
stimulus control) and cognitive (eg, cognitive restructuring) components, as well as relaxation strategies (eg, progressive muscle
relaxation and autogenic training) and sleep hygiene education.
Sleep restriction therapy (SRT) was the second active treatment in
this RCT and is considered an effective standalone behavioral
treatment for insomnia [31]. Although SRT actually predates CBTI,
SRT is now commonly packaged as part of CBTI and is considered a
critical element. As CBTI consists of SRT plus multiple other components, SRT is the briefer of the two interventions. Here, SRT was
delivered as a two-week intervention. Speciﬁcally, the initial faceto-face session consisted of reviewing patient sleep history, education and rationale for sleep restriction practices, and behavioral
homework. Then four follow-up sessions (three phone contacts,
each 3e4 days apart, followed by a second face-to-face session)
were delivered across the following two weeks and were used to
titrate sleep schedules based on sleep diary data. SRT as delivered in
this RCT was the same as the sleep restriction component in CBTI,

except that sessions were spaced more closely together (every 3e4
days rather than approximately weekly), and thus prescribed sleep
schedules were based on fewer days of sleep diary data.
2.4. Measures
PSG data were scored by a certiﬁed sleep technician according to
standard procedures by the American Academy of Sleep Medicine's
2012 guidelines [32]. PSG scorers were blind to group. Sleep measures included sleep latency (minutes from lights out to ﬁrst epoch
of sleep), wake after sleep onset (minutes awake post onset), sleep
efﬁciency (proportion of time in bed asleep), and total sleep time
(sleep duration).
All self-report measures were collected via online surveys hosted by Qualtrics, LLC. Prior to treatment, patients reported sociodemographic and health history information.
The Insomnia severity index (ISI) is a seven-item self-report
measure of insomnia symptom severity [33]. Scores range from 0 to
28 with higher scores indicating greater symptom severity. The ISI
was administered at pretreatment, posttreatment, and six-month
follow-up. Recommendations for clinical trials research include
detecting positive insomnia cases based on ISI scores  11, whereas
remission is indicated by ISI scores  7 [34].
The Presleep Arousal Scale's Cognitive factor (PSAS-C) [35] was
used to measure cognitive arousal during the presleep period, ie,
when individuals are in bed attempting to fall asleep. The PSAS
Cognitive scale consists of eight items (eg, ‘review or ponder events
of the day’ and ‘can't shut off your thoughts') and possible scores
range from 8 to 40 with higher scores indicating greater presleep
cognitive arousal.
Presleep somatic arousal was measured using the Presleep
Arousal Scale's Somatic factor (PSAS-S) [35]. The PSAS Somatic scale
consists of eight items (eg, ‘heart racing, pounding, or beating
irregularly’ and ‘a tight, tense feeling in your muscles’) and possible
scores range from 8 to 40 with higher scores indicating greater
presleep cognitive arousal.
2.5. Analysis plan
Analyses were conducted using SPSS version 25. Age,
menopause-related characteristics, and pretreatment PSG sleep
parameters were ﬁrst presented and cross-sectionally compared
across the three treatment conditions to identify group differences before treatment. Next, we examined whether pretreatment objective sleep disturbance as measured by PSG sleep
efﬁciency moderated treatment response. Speciﬁcally, we ran
repeated measures analysis of covariance (ANCOVA) models to
test changes in ISI from pre to posttreatment/follow-up with
Treatment (active treatment [CBTI and SRT] vs control) as a between group factor and pretreatment sleep efﬁciency as a covariate. Notably, CBTI and SRT were combined into a single group,
because our previously published ﬁndings show that they are
both efﬁcacious treatments [36] and our primary focus here is on
PSG Sleep Efﬁciency as a moderator of treatment response, irrespective of modality. Thus, results from this model showed interactions for Treatment X Time (to demonstrate that active
treatment reduced ISI greater than control, which we have reported in greater detail elsewhere [36]) and for PSG sleep efﬁciency X Time to evaluate whether pretreatment objective sleep
disturbance altered trajectory of symptoms over time, irrespective
of condition. Signiﬁcant interactions were then deconstructed
with posthoc independent samples and paired samples t-tests to
describe the observed effects in relation to active treatment vs
control.
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We then tested treatment effects on objective sleep disturbance
(ie, PSG-determined sleep latency, wake after sleep onset, sleep efﬁciency, and total sleep time). We ﬁrst ran 3  2 repeated measures
ANOVA models to examine Treatment  Time interactions for
changes in PSG sleep parameters from pretreatment to
posttreatment/follow-up. Any signiﬁcant Treatment  Time interactions were followed by paired samples t-tests within each
condition to test for potential simple effects. In addition, a crosssectional one-way ANOVA was used to compare mean levels for
each treatment outcome to determine differences in symptom levels
across groups at posttreatment and six-month follow-up. Lastly, we
used multivariate linear regression models to explore whether
changes in presleep cognitive and somatic arousal were associated
with acute changes in objective sleep. Speciﬁcally, we regressed
changes in PSG sleep parameters between pre and posttreatment on
changes in presleep cognitive and somatic arousal.
3. Results
3.1. Participant enrollment and attrition
Refer to Fig. 1 ﬂow chart of study enrollment and participation. A
total of 317 postmenopausal women were screened for eligibility.
Of these individuals, 107 women were ineligible and another 56
declined to participate or had scheduling conﬂicts. 154 postmenopausal women were randomized to treatment: SHE: N ¼ 50,
SRT: N ¼ 52, and CBTI: N ¼ 52. Two subjects in both the SRT and
CBTI conditions were disqualiﬁed during treatment for changes in
medication or new onset comorbid sleep disorder. Thus, recruitment included two more individuals to replace those who were
disqualiﬁed. This resulted in 50 subjects completing treatment in
each of the three conditions. All 150 subjects provided self-reported
posttreatment outcome data, whereas 16% of treatment completers
did not provide follow-up data six months later (Fig. 1). Regarding
PSG data, 147 women completed all three overnight PSGs (pretreatment, posttreatment, follow-up). However, data from several
subjects were lost due to a shared network server failure, thus PSG
data from 113 subjects were available for analysis. Because the
present study focused on objective sleep disturbance, all data reported herein are from the 113 patients with partial or complete
PSG data.
3.2. Screening and sample characteristics
See Table 1 for sample demographics for the full sample and by
treatment condition. Our sample was largely comprised of nonHispanic White and non-Hispanic Black women. Regarding
objectively estimated sleep, mean PSG sleep latency was within
normal limits (11.95 ± 13.48 m), whereas mean PSG wake after
sleep onset was high (78.97 ± 44.29 m), sleep efﬁciency was low
(81.19 ± 9.98), and total sleep time was relatively short
(390.59 ± 46.78 min). One-way ANOVA models revealed treatment groups did not differ on age or pretreatment ISI (Table 1). To
determine whether pretreatment PSG sleep efﬁciency was associated with patient-reported insomnia severity, we compared
patients with pretreatment PSG sleep efﬁciency < 85% vs  85%,
which did not differ in pretreatment ISI scores (14.60 ± 3.58 vs
15.51 ± 4.78, t[110] ¼ 1.15, p ¼ 0.25).
3.3. Pretreatment objective sleep disturbance buffers treatment
response to insomnia therapy
3.3.1. Acute treatment response
We ﬁrst ran a repeated measures ANCOVA model examining
changes in ISI from pre to posttreatment with Treatment (active
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treatments, ie, CBTI and SRT, vs control) as a between group factor
and baseline PSG sleep efﬁciency as a covariate. The
Treatment  Time interaction was signiﬁcant (F[1,108) ¼ 51.43,
p < 0.001 and a posthoc paired-samples t-test showed that patients
who received active treatment reported a mean decrease of 7.5
points on the ISI (t[70] ¼ -12.24, p < 0.001), whereas mean ISI
decreased by just 1.2 points for controls.
The Treatment X PSG Sleep Efﬁciency interaction was also signiﬁcant (F[1,108] ¼ 10.64, p ¼ 0.001) such that patients with lower
pretreatment sleep efﬁciency exhibited smaller improvements in
ISI by the end of treatment. An independent samples t-test showed
that posttreatment ISI scores were lower for patients with low
pretreatment sleep efﬁciency compared to those with high sleep
efﬁciency (8.47 ± 5.53 vs 10.98 ± 4.73, t[111]¼2.60, p¼.01).
We then evaluated treatment outcomes related to objective
sleep disturbance within active treatment and then within the
control condition. Among patients receiving active treatment,
pretreatment sleep efﬁciency was negatively correlated with
change scores in ISI such that lower sleep efﬁciency was associated
with smaller decreases in symptoms (Table 2). Notably, mean ISI
scores did not differ before treatment between patients with high
vs low sleep efﬁciency (Table 3). However, after active treatment,
posthoc descriptive comparisons showed that patients with high
pretreatment sleep efﬁciency, relative to those with low sleep efﬁciency, reported lower insomnia symptom severity and higher
rates of remission (Table 3). Speciﬁcally, patients in active treatment with high pretreatment sleep efﬁciency had a mean reduction
of 9.2 points on the ISI, whereas patients with low efﬁciency only
reported an ISI reduction of 5.9 points, (t[70] ¼ 2.79, p ¼ 0.007,
Cohen's d ¼ 0.68). This suggests that response to insomnia therapies for patients with objective sleep disturbance is ~33% lower
than response for patients without objective sleep ﬁndings. This
pattern was not replicated in the control condition (Tables 2 and 3).
See Supplementary Table 1 for pre and posttreatment mean ISI
scores for patients with high and low sleep efﬁciency across all
three conditions.
3.3.2. Long-term treatment response
A repeated measures ANCOVA examining changes in ISI from
pretreatment to six-month follow-up again showed that the
Treatment  Time interaction was signiﬁcant (F[1,109) ¼ 54.25,
p < 0.001. In addition, the Treatment X Sleep Efﬁciency interaction
was also signiﬁcant (F[1,99] ¼ 5.14, p ¼ 0.02) such that lower pretreatment sleep efﬁciency predicted smaller gains in insomnia
improvement through six-month follow-up.
Among those in active treatment, pretreatment sleep efﬁciency
was associated with longer-term reductions in ISI such that lower
objective sleep disturbance before treatment was associated with
greater reductions in ISI over the long-term (Table 2). Even so,
posthoc descriptive comparisons showed that ISI scores did not
differ between patients with high or low sleep efﬁciency at sixmonth follow-up, although remission rates approached signiﬁcance (Table 3). In the control condition, pretreatment sleep efﬁciency was once again not associated with changes in ISI scores nor
clinical outcomes at six-month follow-up (Tables 2 and 3). See
Supplementary Table 1 for follow-up mean ISI scores for patients
with high and low sleep efﬁciency across all three conditions.
3.4. CBTI vs SRT vs SHE control treatment effects on objective sleep
disturbance
3.4.1. Sleep latency
See Table 4 for sleep latency means and standard deviations for
all groups at posttreatment and six-month follow-up. Also see Fig. 2
for visual representation of data. When testing acute treatment
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Fig. 1. Patient ﬂowchart for recruitment and study protocol.

effects, a repeated measures ANOVA showed that sleep latency did
not signiﬁcantly change for the full sample between pre and
posttreatment (F[1,106] ¼ 0.82, p ¼ 0.37). However, a signiﬁcant
Treatment  Time interaction was observed (F[2,106] ¼ 3.23,
p ¼ 0.04). We then ran series of posthoc paired samples t-tests to
identify group(s) wherein sleep latency signiﬁcantly changed during treatment. In the SRT group, sleep latency signiﬁcantly
decreased by 5 min (t[33] ¼ 3.24, p ¼ 0.003). To the contrary, no
signiﬁcant within-group changes in sleep latency were observed
for CBTI (p ¼ 0.27) or SHE (p ¼ 0.74). Despite the signiﬁcant
reduction in sleep latency in the SRT group, a one-way ANOVA
revealed no posttreatment group differences in sleep latency
(Table 4).
A repeated measures ANOVA also showed that PSG sleep latency
did not signiﬁcantly change from pretreatment to six-month
follow-up (F[1,104] ¼ 2.26, p ¼ 0.14) nor was a Treatment  Time
interaction observed (F[2,104] ¼ 0.85, p ¼ 0.43). Consistent with
these null ﬁndings, a one-way ANOVA revealed no group differences in sleep latency six months after treatment.

3.4.2. Wake after sleep onset
See Table 4 for wake after sleep onset means and standard deviations for all groups at posttreatment and six-month follow-up.
Also see Fig. 2 for visual representation of data. When exploring
acute changes in sleep maintenance, a repeated measures ANOVA
revealed that PSG wake after sleep onset decreased by 11 min for
the full sample, which was a signiﬁcant reduction (F[1,106] ¼ 5.86,
p ¼ 0.02). Despite this acute reduction in wake after sleep onset, no
Treatment  Time interaction was observed (F[2,106] ¼ 1.08,
p ¼ 0.34). Consistent with this null interaction ﬁnding, a one-way
ANOVA revealed no posttreatment group differences in PSG wake
after sleep onset (p ¼ 0.79; Table 4).
Findings from the six-month follow-up data were consistent
with acute models. A repeated measures ANOVA again showed that
wake after sleep onset decreased by 11 min from pretreatment to
six-month follow-up (F[1,104] ¼ 4.19, p ¼ 0.04). Yet, once again, the
Treatment  Time interaction was non-signiﬁcant (F[2,104] ¼ 2.49,
p ¼ 0.09) and no group differences in wake after sleep onset were
observed (p ¼ 0.21; Table 4).
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Table 1
Sample characteristics prior to treatment (n ¼ 113).

Sample size
Age (M±SD)
Race (n; %)
White
Black
Hispanic or Latinx
Not reported
Years since last menses (M±SD)
Hormone Replacement Therapy (n; %)
Medical/Surgical Menopause (n; %)
ISI, prior to treatment (M±SD)

All subjects

SHE

SRT

CBTI

113
56.40 ± 5.34 y

42
57.21 ± 5.30

37
56.68 ± 5.18

34
55.09 ± 5.46

F(2,110) ¼ 1.58, p ¼ 0.21

56; 49.6%
51; 45.1%
1; 0.9%
5; 4.4%
7.19 ± 7.24
3; 2.7%
27; 23.9%
15.04 ± 4.15

20; 47.6%
20; 47.6%
e
2; 4.8%
7.62 ± 8.01
2; 4.8%
7; 16.7%
14.86 ± 4.45

21; 56.8%
13; 35.1%
1; 2.7%
2; 5.4%
6.42 ± 6.62
1; 2.7%
9; 24.3%
15.16 ± 3.80

15; 44.1%
18; 54.5%
e
1; 2.9%
7.51 ± 7.06
0; 0.0%
11; 32.4%
15.12 ± 4.23

F(2,110) ¼ 0.29, p ¼ 0.75
c2 ¼ 1.65, p ¼ 0.44
c2 ¼ 2.55, p ¼ 0.28
F(2,110) ¼ 0.06, p ¼ 0.94

Note: SHE ¼ sleep hygiene education control. SRT ¼ sleep restriction therapy. CBTI ¼ cognitive behavioral therapy for insomnia. PSG ¼ polysomnography. m ¼ minutes. Sleep
latency ¼ minutes from lights out to ﬁrst epoch of sleep. Wake after sleep onset ¼ minutes awake post sleep onset. Sleep efﬁciency ¼ proportion of time in bed spent asleep X
100. Total sleep time ¼ minutes spent asleep during total PSG recording. F ¼ F-statistic for one-way analysis of variance to compare means across SHE, SRT, and CBTI groups. c
[2] ¼ chi-square statistic to compare proportions across SHE, SRT, and CBTI groups. p ¼ signiﬁcance vale.

Table 2
Correlations between pretreatment sleep efﬁciency and changes in insomnia
symptom severity among patients in active treatment and in the control condition.

Active Treatment
Pretreatment SE
Control Condition
Pretreatment SE

ISIT2-T1

ISIT3-T1

-0.37**

-0.29*

-0.10

-0.07

Note: Active treatment includes CBTI and SRT participants. Control condition includes sleep hygiene education control participants. ISIT2-T1 ¼ change in insomnia
severity index score from pretreatment to posttreatment. ISIT3-T1 ¼ change in
insomnia severity index score from pretreatment to 6-month follow-up. SE ¼ PSGdeﬁned sleep efﬁciency.

3.4.3. Sleep efﬁciency
See Table 4 and Fig. 2 for PSG sleep efﬁciency results. Repeated
measures ANOVA models revealed no acute changes in sleep efﬁciency (F[1,106] ¼ 2.25, p ¼ 0.11), whereas PSG sleep efﬁciency
increased by ~2% for the full sample by six-month follow-up (F
[1,104] ¼ 5.63, p ¼ 0.02). Even so, no Treatment  Time interaction
was observed for acute (p ¼ 0.11) or long-term (p ¼ 0.09) effects. No
treatment condition differences in sleep efﬁciency were observed
at posttreatment (p ¼ 0.54) or six months later (p ¼ 0.24; Table 4).
3.4.4. Total sleep time
As time in bed was ﬁxed, results for total sleep time therefore
mirror sleep efﬁciency data (Table 4, Fig. 2). Thus, we will simply
acknowledge that no Treatment  Time interactions were observed

and no group differences at posttreatment or six-month follow-up
were signiﬁcant.
3.5. Exploring associations between presleep arousal and objective
sleep disturbance
Prior to treatment, multivariate linear regression showed that
PSG sleep latency was signiﬁcantly associated with presleep
cognitive arousal, but not with presleep somatic arousal (Table 5).
Neither cognitive nor somatic arousal was associated with PSG
wake after sleep onset. Posttreatment data replicated pretreatment
data such that PSG sleep latency was signiﬁcantly associated with
presleep cognitive arousal, whereas somatic arousal was nonsigniﬁcant (Table 5). Posttreatment PSG wake after sleep onset was
not associated with cognitive nor somatic arousal.
Lastly, we conducted two multivariate linear regression models
to test whether acute improvements in presleep arousal were
associated with improvements in objective sleep (Table 5).
Consistent with pre and posttreatment models, reductions in PSG
sleep latency were signiﬁcantly associated with reductions in presleep cognitive arousal, but not with changes in somatic arousal.
Changes in wake after sleep onset were not associated with
changes in cognitive nor somatic arousal.
4. Discussion
In postmenopausal women with chronic insomnia and PSGdeﬁned objective sleep maintenance difﬁculties, patients with

Table 3
Descriptive comparisons of insomnia symptom severity and remission rates across treatment between patients with and without objective sleep disturbance
(Mean ± Standard Deviations presented).
Pretreatment

Posttreatment

6-Month Follow-up

Patients in active treatment
ISI

Symptom Severity

Symptom Severity

Remission Rates

Symptom Severity

Remission Rates

SE  85%
SE < 85%

t(69) ¼ -0.67, p ¼ 0.51
15.47 ± 4.44
14.84 ± 3.56

t(69) ¼ 2.64, p ¼ .01, d ¼ 0.63
6.29 ± 4.24
8.92 ± 4.13

c2 ¼ 4.06, p ¼ 0.04, RR ¼ 1.63
21/34; 61.8%
14/37; 37.8%

t(63) ¼ 1.55, p ¼ 0.13
6.63 ± 4.99
8.54 ± 4.94

c2 ¼ 3.28, p ¼ 0.07
22/30; 73.3%
18/35; 51.4%

Patients in control condition.
ISI

Symptom Severity

Symptom Severity

Remission Rates

Symptom Severity

Remission Rates

SE  85%
SE < 85%

t(39) ¼ -0.92, p.36
15.60 ± 5.63
14.27 ± 3.66

t(39) ¼ 0.20, p ¼ .84
13.40 ± 5.01
13.69 ± 4.07

c2 ¼ 0.16, p ¼ 0.69

t(35) ¼ -0.34, p.74
13.54 ± 6.17
12.96 ± 4.19

c2 ¼ 0.69, p ¼ 0.41
3/24; 12.5%
3/13; 23.1%

1/26; 3.8%
1/15; 6.7%

Note: Active treatment includes CBTI and SRT participants. Control condition includes sleep hygiene education control participants. ISI ¼ insomnia severity index. t ¼ t-statistic
for independent samples t-test. p ¼ signiﬁcance value. c2 ¼ chi-square. SE ¼ sleep efﬁciency. SE  85% ¼ high sleep efﬁciency before treatment reﬂecting no objective sleep
disturbance. SE < 85% ¼ low sleep efﬁciency before treatment reﬂecting objective sleep disturbance.
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Table 4
Comparing CBTI vs SRT vs sleep hygiene education on objective sleep parameters.

Sleep latency
SHE
SRT
CBTI
Wake after sleep onset
SHE
SRT
CBTI
Sleep efﬁciency
SHE
SRT
CBTI
Total sleep time
SHE
SRT
CBTI

Pretreatment

Posttreatment

6-month Follow-up

Group Comparisons

Group Comparisons

Group Comparisons

F(2,110) ¼ 0.15, p ¼ 0.86
12.45 ± 17.33 m
12.35 ± 12.21 m
10.88 ± 8.92 m
F(2,110) ¼ 1.09, p ¼ 0.34
81.82 ± 42.95 m
84.25 ±0 .51.15 m
67.97 ± 37.15 m
F(2,11) ¼ 1.02, p ¼ 0.36
80.58 ± 9.88
80.01 ± 10.94
83.20 ± 8.94
F(2,110) ¼ 0.62, p ¼ 0.54
388.92 ± 45.98 m
385.84 ± 52.23 m
397.82 ± 41.72 m

F(2,108) ¼ 1.82, p
11.66 ± 16.78 m
6.38 ± 5.30 m
13.37 ± 20.91 m
F(2,108) ¼ 0.24, p
70.80 ± 39.54 m
64.17 ± 29.83 m
68.06 ± 54.26 m
F(2,108) ¼ 0.64, p
82.74 ± 10.16
85.31 ± 6.34
83.08 ± 13.61
F(2,108) ¼ 0.62, p
397.46 ± 48.97 m
409.68 ± 30.42 m
399.43 ± 65.19 m

F(2, 108) ¼ 1.02, p
8.77 ± 6.83 m
10.44 ± 11.23 m
12.22 ± 12.75 m
F(2, 108) ¼ 1.58, p
77.77 ± 51.04 m
58.54 ± 32.94 m
68.34 ± 51.95 m
F(2, 108) ¼ 1.28, p
82.01 ± 10.58
85.71 ± 7.15
83.25 ± 11.78
F(2, 108) ¼ 1.43, p
394.38 ± 50.65 m
413.25 ± 33.62 m
400.74 ± 57.20 m

¼ 0.17

¼ 0.79

¼ 0.56

¼ 0.54

¼ 0.36

¼ 0.21

¼ 0.28

¼ 0.24

Note: SHE ¼ sleep hygiene education control. SRT ¼ sleep restriction therapy. CBTI ¼ cognitive behavioral therapy for insomnia. PSG ¼ polysomnography. m ¼ minutes. Sleep
latency ¼ minutes from lights out to ﬁrst epoch of sleep. Wake after sleep onset ¼ minutes awake post sleep onset. Sleep efﬁciency ¼ proportion of time in bed spent asleep X
100. Total sleep time ¼ minutes spent asleep during total PSG recording. F ¼ F-statistic for one-way analysis of variance to compare means across SHE, SRT, and CBTI groups.
p ¼ signiﬁcance vale.

Fig. 2. Pretreatment, posttreatment, and follow-up PSG sleep latency, wake after sleep onset, sleep efﬁciency, and total sleep time data for CBTI, SRT, and SHE (means and standard
errors presented).

greater objective sleep disturbance prior to treatment reported
smaller gains on self-report measures of insomnia symptoms after
therapy, relative to patients with less objective sleep disturbance.
These data suggest that insomnia patients with objective sleep
disturbance may respond more poorly to cognitive and behavioral
insomnia treatments than patients without objective sleep ﬁndings. Not only did objective sleep disturbance appear to blunt
treatment response, but CBTI and SRT exerted no therapeutically
beneﬁcial effects on objective sleep disturbance relative to control.
Some evidence suggested that sleep latency could potentially be
reduced with sleep restriction, but it is unclear whether this effect
would be durable or clinically meaningful. Even so, patients who
reported decreases in nocturnal cognitive arousal also exhibited

reductions in sleep latency on PSG, which suggests that nocturnal
cognitive arousal might represent an entry point for cognitivebehavioral interventions to reduce objective sleep latency in patients presenting with trouble falling asleep.
4.1. Objective sleep disturbance as a moderator of treatment
response
Patients with lower PSG sleep efﬁciency before treatment had
poorer acute and long-term self-reported insomnia outcomes
relative to insomnia patients without objective ﬁndings. Important
to emphasize here is that low PSG sleep efﬁciency before treatment
was not associated with pretreatment patient-reported insomnia
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Table 5
Associations of presleep cognitive and somatic arousal with objective sleep disturbance.
b
Pretreatment Sleep latency
Pretreatment PSAS-C
Pretreatment PSAS-S
Posttreatment Sleep latency
Pretreatment PSAS-C
Pretreatment PSAS-S
D Sleep latency
D PSAS-C
D PSAS-S

b

p

0.90
0.06

0.26
0.03

0.01
0.74

1.89
-0.44

0.50
-0.18

0.001
0.19

1.34
-0.17

0.28
-0.06

0.04
0.64

b
Pretreatment Wake after sleep onset
Pretreatment PSAS-C
-0.27
Pretreatment PSAS-S
-0.83
Posttreatment Wake after sleep onset
Pretreatment PSAS-C
1.37
Pretreatment PSAS-S
-0.23
D Wake after sleep onset
D PSAS-C
0.26
D PSAS-S
-0.19

b

p

-0.02
-0.14

0.83
0.19

0.12
-0.03

0.42
0.83

0.02
-0.02

0.89
0.86

Note: b ¼ unstandardized regression coefﬁcient. b ¼ standardized regression coefﬁcient. p ¼ statistical signiﬁcance. PSAS-C ¼ presleep arousal scale, cognitive factor. PSASS ¼ presleep arousal scale, somatic factor. Sleep latency ¼ minutes from lights out to ﬁrst epoch of sleep. Wake after sleep onset ¼ minutes awake post sleep onset. D Sleep
latency ¼ Change in PSG-based sleep latency from pre to posttreatment. D Wake after sleep onset ¼ Change in PSG-based wake after sleep onset from pre to posttreatment. D
PSAS-C ¼ Change in presleep arousal scale cognitive factor scores from pre to posttreatment. D PSAS-S ¼ Change in presleep arousal scale somatic Factor scores from pre to
posttreatment.

severity, thus pretreatment objective sleep disturbance is not
merely a proxy for patient-reported illness severity. Among patients receiving CBTI or SRT, those with greater objective sleep
disturbance had smaller acute and long-term insomnia improvements and lower rates of remission after therapy relative to those
without objective sleep difﬁculties. In the control group, treatment
outcomes did not differ as a function of pretreatment objective
sleep disturbance. These results are consistent with prior reports
suggesting that objective short sleep blunts response to CBTI
[12,13], but contrary to reports that show no difference in insomnia
therapy outcomes between insomnia patients with normal vs short
objective sleep duration [15e17].
Reasons why our study supported objective sleep disturbance as
a moderator of treatment outcomes in insomnia (as ﬁndings in the
ﬁeld are highly mixed) are not readily clear, but we can speculate
based on notable differences in our methodology. One potential
explanation is that our entry criteria included minimal requirements for objective wake after sleep onset. Prior CBTI trials
with PSG outcomes have not required objective nocturnal wakefulness and may have thus suffered from restriction of range [9]. In
addition, our primary analyses for examining objective sleep
disturbance as a moderator centered on sleep efﬁciency as a
continuous variable, rather than dichotomizing the sample into two
subgroups. Preserving the dimensional aspect of objective sleep
disturbance may have retained sufﬁcient statistical power to detect
moderating effects of objective sleep disturbance on treatment
outcomes, which may have been lost if we tested our hypotheses by
dichotomizing the sample into two subgroups (as observed in our
posthoc descriptive comparisons between patients with high vs
low sleep efﬁciency based on the <85% cutoff). This is especially
critical in the absence of empirically supported PSG sleep
efﬁciency-based clinical cutoff criteria for phenotypes.

Indeed, no consensus PSG criteria have been ﬁrmly established
to classify the objective sleep disturbance phenotype. A lack of
standardization is reﬂected by myriad operationalizations of
objective sleep disturbance in insomnia research (eg, < 85% sleep
efﬁciency, < 6.5 h total sleep time, > 30 min sleep latency, etc.) [8].
Recently, empirical support for short objective sleep duration (<6 h
total sleep time, ideally assessed via PSG) as a robust indicator of
objective sleep disturbance in insomnia has ﬂourished
[10,11,37e39], yet it is unclear whether other PSG criteria can also
identify insomnia patients with other distinct and clinically
meaningful patterns of objective sleep disturbance.
Although insomnia with short sleep duration has garnered
much deserved attention, it is possible that short sleep is just one
clinically meaningful indicator of objective sleep disturbance. If
other indicators of signiﬁcant objective sleep disturbance exist,
then it is possible that a lack of consideration for these other potential manifestations of objective sleep disturbance in insomnia
have contributed to mixed ﬁndings in the ﬁeld. Along these lines,
objective short sleep reﬂects physiologic hyperarousal in the
context of insomnia. It is thus critical to determine whether physiologic hyperarousal underlies other forms of objective sleep
disturbance (prolonged latency, extended wake after sleep onset,
etc.). Future large-scale research is needed to identify valid and
reliable objective criteria to differentiate between insomnia patients with and without objective ﬁndings, potentially in addition
to the widely supported short sleep phenotype, and to characterize
the psychological and neurobiological underpinnings, as well as
characterize morbidity, mortality, and treatment-responsivity
related to any indicators of objective sleep disturbance in
insomnia. If objective ﬁndings are clearly established and reﬁned,
then clinical trials research will be better positioned to determine
whether triage based on objective criteria can improve treatment
outcomes.

4.2. Operationalizing objective sleep disturbance in insomnia: the
need to identify a clinical indicator
Our reasoning behind operationalizing objective sleep disturbance as pretreatment sleep efﬁciency on PSG was twofold: (1)
sleep efﬁciency is encompassing in that it captures sleep latency,
wake time during sleep, and early morning awakenings, and (2) no
clear cutoff deﬁning objective sleep disturbance exists in the literature, thus examining sleep efﬁciency as a continuous variable at
present may be preferable. Important to emphasize here is that this
study's posthoc group comparisons based on < 85% sleep efﬁciency
were for descriptive purposes and in alignment with clinical
thresholds in behavioral sleep medicine used to guide decisions in
therapy protocol, but are not intended to elucidate phenotypes.

4.3. Objective sleep disturbance as a treatment outcome in
insomnia therapy
A notable strength of our RCT over prior trials is that we required
objective sleep disturbance per PSG for study entry. Despite oversampling insomnia patients with objective ﬁndings, we did not
observe any meaningful effects of CBTI or SRT on objective sleep at
posttreatment or six-month follow-up, relative to control. Our
ﬁndings, in combination with results from a recent meta-analysis of
ﬁve high quality clinical trials [9], suggest that insomnia therapies
may not exert changes to objective sleep disturbance in a clinically
meaningful way. Yet, there is ample opportunity in future research
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to augment CBTI and SRT to enhance treatment effects of psychological intervention on objective nocturnal wakefulness.
Although evidence suggests that insomnia and objective sleep
disturbance are most toxic when co-occurring [10,11], objective
sleep disturbances alone have nevertheless been linked to negative
health consequences including depression and increased perceived
stress, obesity and obesogenic behaviors, and cardiometabolic
dysregulation [40e43]. Thus, enhancing insomnia therapies to
better improve sleep in insomnia patients with these objective
ﬁndings is an important endeavor for clinical sleep research,
especially given growing evidence that patients with objective
sleep may not experience adequate alleviation of self-reported
symptoms with insomnia therapy. Research is needed to identify
therapeutic targets that may serve as entry points to therapeutically and durably improve objective sleep through psychological or
pharmacological interventions.
4.4. Can reducing nocturnal cognitive arousal improve objective
sleep disturbance?
Prior and after treatment, nocturnal cognitive arousal levels
were positively associated with PSG sleep latency, which is
consistent with prior reports [22e27]. Moreover, we found that
changes in nocturnal cognitive arousal were associated with
changes in sleep latency such that decreases in nocturnal cognitive
arousal were linked to falling asleep faster on PSG. In contrast,
nocturnal cognitive arousal was not associated with sleep maintenance difﬁculties. Self-reported somatic arousal at night was not
associated with latency or maintenance parameters on PSG.
Although our data and prior studies [9] indicate that standard
CBTI and SRT may not therapeutically beneﬁt objective wakefulness
at night, identifying the connection between nocturnal cognitive
arousal and objective sleep latency offers a potential entry point to
improve patients’ ability to fall asleep. Standard CBTI does not
emphasize focus on cognitive arousal such as rumination or worry,
nor is cognitive arousal considered a key therapeutic target. Unsurprisingly, CBTI has not demonstrated strong or robust effects on
the tendency to ruminate or worry [20,44], although even modest
reductions in cognitive-emotional arousal facilitate treatmentresponse in CBTI [45]. As experimental studies show that
inducing rumination prolongs PSG and actigraphy-deﬁned sleep
latency [22e26], we may consider that therapeutically reducing
nocturnal cognitive arousal with insomnia therapies augmented to
better target these cognitive-emotional symptoms may have
downstream effects on objective sleep. Future studies should
determine whether enhancing CBTI (or other efﬁcacious insomnia
therapies) to defuse ruminative thought processes may improve
objective sleep measures. Potential therapies and/or augmentation
strategies to better improve cognitive-emotional arousal in
insomnia may include cognitive therapy for insomnia [46],
mindfulness-based therapy for insomnia [47], and even components of rumination-focused cognitive behavioral therapy [48] or
emotion regulation therapy [49].
4.5. Limitations and future directions
The present study should be interpreted in light of certain
limitations. Our primary limitation concerns limits of generalizability related to our patient population. As these patients reported
insomnia that onset or was exacerbated by the menopause transition, results from our postmenopausal sample may not generalize
to men or younger women. Further, etiological processes for
menopausal insomnia may differ compared to the broader adult
insomnia population. Indeed, levels of nocturnal cognitive arousal
were lower in this sample than what has been reported by other

insomnia patient populations, which may reﬂect differing etiology.
Given the strong association between cognitive arousal and sleep
latency, it is unsurprising then that PSG sleep latencies were largely
within normal limits for this sample per quantitative criteria for
objective ﬁndings [50]. Thus, the nature of our sample limited our
ability to detect potential CBTI and SRT treatment effects on PSG
sleep latency due to restricted range. Relatedly, our study included
entry criteria for PSG-based wake after sleep onset. While this is a
strength for detecting improvements in objective sleep, this entry
criterion limited may have contributed to our inability to testing
other operationalizations of objective sleep disturbance by producing under-representation of patients with prolonged objective
sleep latency and over-representation of those with objective sleep
maintenance. Future studies testing treatment effects of CBTI and
SRT should do so in more representative samples that allow testing
different operationalizations of objective sleep disturbance, which
may provide important evidence regarding clinical utility.
Notably, in the present study, all subjects were required to stay
in bed for 8 h each night. Although this standardizes observation, it
also creates a behavioral demand for maintaining sleep while being
recorded, which itself could disrupt sleep. Along these lines, the
pattern of wake after sleep onset may have been altered with CBTI
or SRT. That is, if pretreatment sleep maintenance issues were
widespread throughout the night, but then consolidated to early
morning awakenings, this may thereby reﬂect consolidated sleep
with early morning awakening possibly indicating that the patient
does not need the full 8 h of sleep allotted to them.
It is possible or even likely that sleep restriction (as a standalone
treatment or as a component of CBTI) decreases objective sleep
latency, particularly before complete titration of the sleep period.
Even so, acute reductions in sleep latency are not necessarily
therapeutic or beneﬁcial if (1) pretreatment sleep latency is not
excessive and (2) acute gains are not durable over the long-term.
Notably, posttreatment PSG in the SRT was two weeks after treatment began, whereas PSG after CBTI was conducted after ~six
weeks of therapy. Therefore, it is possible that any acute sleep
restriction-related changes in PSG sleep latency in the CBTI group
were observable before titrating sleep schedules out. Research is
needed to determine whether insomnia patients with prolonged
objective sleep latency may experience a substantial and durable
decrease in latency (on actigraphy or PSG) in response to sleep
restriction (as standalone treatment or a component of CBTI) or
whether acute movement on this index merely reﬂects acute sleep
deprivation.
By extension, we previously reported that CBTI and SRT had no
clinically meaningful effects on rumination and worry in this
sample [20] and, in the present study, we showed that these
therapies largely did not improve objective sleep relative to control.
Despite the lack of treatment effects, we observed that decreases in
nocturnal cognitive arousal were associated with decreases in PSG
sleep latency. But because these treatments are ill-designed to
improve ruminative cognitive processes or objective sleep, the
observed effect size in the present study may be underestimated.
Further, it is possible that decreases in cognitive arousal may also be
associated with other changes in objective sleep, but that a lack of
treatment effects on cognitive arousal and objective sleep prevented our ability to detect such effects. Finally, the small sample
size and PSG data loss may have limited our ability to detect effects
by reducing statistical power. Even so, null ﬁndings presented here
are consistent with the extant literature.
5. Conclusions
Postmenopausal insomnia patients with objective sleep disturbance appeared to have blunted treatment response to CBTI and
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SRT, whereas patients without objective sleep ﬁndings were more
responsive to these insomnia therapies. In addition, cognitive and
behavioral treatments for insomnia produced limited improvement
in objective nocturnal wakefulness, yet alleviation of objective
sleep disturbance was not necessary for insomnia remission based
on patient-reported outcomes. It remains unclear, however,
whether enhancing treatment effects on objective sleep could
potentially improve outcomes for insomnia patients with objective
sleep ﬁndings. Despite the lack of robust treatment effects,
exploratory analyses suggest that reductions in nocturnal cognitive
arousal are linked to reductions in objective sleep latency. This
identiﬁes cognitive arousal as a potential therapeutic target (and
potential triaging variable) to facilitate improvements in objective
sleep. Even so, therapeutic targets for psychological insomnia interventions to improve objective sleep maintenance remain
elusive. Augmentation strategies using pharmacotherapy, possibly
involving newer wake-inhibiting orexin antagonists that produce
superior effects on objective total sleep time and sleep maintenance than sleep-promoting benzodiazepine receptor agonists
[51,52], may enhance response to insomnia therapy in patients with
objective sleep disturbance.
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Appendix A. Supplemental Table 1. Mean ISI scores across
treatment conditions at pretreatment, posttreatment, and 6month follow-up for patients with high and low PSG sleep
efﬁciency

Pretreatment
Patients with PSG sleep efﬁciency  85%
ISI
F(2,46) ¼ 0.19, p ¼ 0.83
SHE
15.60 ± 5.63
SRT
14.86 ± 4.62
CBTI
15.90 ± 4.78
Patients with PSG sleep efﬁciency < 85%
ISI
F(2,60) ¼ 0.62, p ¼ 0.54
SHE
SRT
CBTI

14.27 ± 3.66
15.35 ± 3.31
14.00 ± 3.90

Posttreatment

6-Month
Follow-up

F(2,46) ¼ 14.71,
p < 0.001
13.40 ± 5.01bc
7.71 ± 4.10a
5.30 ± 4.14a

F(2,40) ¼ 8.89,
p ¼ 0.001
13.54 ± 6.17c
8.42 ± 4.42
5.44 ± 5.11a

F(2,60) ¼ 10.33,
p < 0.001
13.69 ± 4.07bc
9.17 ± 4.13a
8.50 ± 4.24a

F(2,56) ¼ 6.30,
p ¼ 0.003
12.96 ± 4.19bc
8.52 ± 4.49a
8.58 ± 5.93a

Note: PSG sleep efﬁciency as measured on the control night prior to treatment.
ISI ¼ insomnia severity index. SHE ¼ sleep hygiene education control. SRT ¼ sleep
restriction therapy. CBTI ¼ cognitive behavioral therapy for insomnia. F ¼ F-ratio
for one-way analysis of variance models comparing mean ISI scores at each timepoint for descriptive purposes. p ¼ signiﬁcance value. Posthoc contrasts were run
using Bonferroni method and signiﬁcant contrasts are noted as such: a group mean
differs from SHE, b group mean differs from SRT, c group mean differs from CBTI.
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